Evaluating Elanco Animal Health: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
Elanco Animal Health (NYSE:ELAN) has received mixed analyst ratings over the past three months, with a recent average 12-month price target of $19.0, down from $20.0. Analysts have varied in their ratings, with some lowering and others maintaining their price targets. Elanco's financials show a 12.02% revenue growth but challenges in profitability and returns.
October 28, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Elanco Animal Health has received mixed analyst ratings, with a recent average price target of $19.0, indicating a 5% drop from previous targets. Analysts have varied in their ratings, with some lowering and others maintaining their price targets. The company's financials show a 12.02% revenue growth but challenges in profitability and returns.
The mixed analyst ratings and the reduction in the average price target suggest a neutral short-term impact on Elanco's stock price. While the company shows revenue growth, its profitability challenges and lower-than-average returns may offset positive sentiment. The varied analyst opinions reflect uncertainty in the market, leading to a neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100